Global Overactive Bladder Therapeutics Market Analysis 2019-2023 - ResearchAndMarkets.com

DUBLIN--()--The "Overactive Bladder Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The overactive bladder (OAB) therapeutics market analysis considers sales from anticholinergics. Beta-3 adrenergic agonists, and other OAB therapeutics. The analysis also considers the sales of overactive bladder therapeutics in Asia, Europe, North America, and RoW.

In 2018, the anticholinergics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as increasing availability of branded drugs and rise in popularity of combination therapy will play a significant role in the anticholinergics segment to maintain its market position.

Also, the global overactive bladder therapeutics market report looks at factors such as the increasing number of drug approvals, the advent of combination therapy, and strategic alliance. However, extensive use devices to treat OAB, side effects associated with OAB, and rising patent litigations may hamper the growth of the overactive bladder therapeutics industry over the forecast period.

The advent of combination therapy

The launch of combination therapy offers patients an efficacious pharmacological regime which requires shorter duration for treatment and reduces the overall cost associated with medication treatment. Astellas was the first vendor to introduce a combination therapy, which exhibits higher efficacy with fewer side-effects. This advent of combination therapy will lead to the expansion of the global overactive bladder therapeutics market at a CAGR of almost 2% during the forecast period.

The advent of gene therapy

The treatment therapy available for OAB involves the use of small molecules, which helps in the relaxation of smooth muscles in the urinary bladder to control the emptying of the bladder. The medication therapy, which is used exerts its pharmacological effect by suppressing the overactivity of the detrusor muscle.

The drugs used in the therapy are associated with certain side effects like dry mouth, constipation, blurred vision, and cognitive impairment. Thus, there is a need for the development of biological drugs targeting the gene and consequently improving bladder functioning. The ongoing research in this area is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of several major players, the global overactive bladder therapeutics market is moderately fragmented. The robust vendor analysis is designed to help clients improve their market position. This report provides a detailed analysis of several leading overactive bladder therapeutics manufacturers, that include:

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Camber Pharmaceuticals Inc.
  • Endo International PLC
  • KYORIN Holdings Inc.
  • Merck & Co. Inc.
  • Mylan N.V.
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

Also, the overactive bladder therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Key Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE LANDSCAPE

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Comparison by product
  • Anticholinergics - Market size and forecast 2018-2023
  • Beta-3 adrenergic agonists - Market size and forecast 2018-2023
  • Other OAB therapeutics - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • RoW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

PART 12: MARKET TRENDS

  • Advent of gene therapy
  • Rising risk factors of OAB
  • Growing geriatric population

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Camber Pharmaceuticals Inc.
  • Endo International PLC
  • KYORIN Holdings Inc.
  • Merck & Co. Inc.
  • Mylan N.V.
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/yfdhlg

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900